Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Febrile Neutropenia 6Neutropenia 5Neoplasms 4Infections 4Fever 4Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Urinary Tract Infections 1Stomach Neoplasms 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Arterial Hypertension 1Pseudomonas Infections 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1

Interventions

sipuleucel-T 2enzalutamide 2pamiparib 1gallium 68 PSMA-11 1fluzoparib 1Vancomycin 1Prednisone 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Vancomycin × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡